Altitude Sickness Clinical Trial
Official title:
Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness: A Randomized Controlled Trial
This study evaluates the safety and efficacy of the voluntary ventilatory response as prophylaxis for acute mountain sickness, measured by the Lake Louise Self-Report Score, comparing to a group using acetazolamide.
Rationale: Acute mountain sickness (AMS) is a common condition among people who go to
altitude and stay at altitude. Acclimatization is the most important mechanism in order to
reduce the risk of AMS, however, this is not possible or adequate in a large part of the
cases. Recently, there are indications that adjustment of respiration by means of a
voluntary increase in the respiratory minute volume can have a similar prophylactic effect.
The purpose of this study is to measure the effect of the voluntary increase of the minute
volume by means of controlled hyperventilation as prophylaxis for acute mountain sickness
without prior acclimatization, with AMS being expressed in the Lake Louise Self-Report Score
(LLSRS).
Objective: To investigate the safety and efficacy of the voluntary increase in minute
ventilation by means of controlled hyperventilation as prophylaxis for AMS, measured by the
LLSRS in a randomized controlled trial ascending to 4954m altitude.
Study design: Prospective randomized controlled trial, safety and efficacy.
Study population: 30 healthy subjects
Intervention: The investigational prophylaxis is controlled hyperventilation. Participants
in the interventional group will be trained to hyperventilate in a controlled fashion doing
a series of exercises during the 4 days prior to the ascent. They will also be taught in a
practical way to recognize early clinical signs and symptoms of hypocapnia.
Main study parameters/endpoints: Safety and efficacy measured by comparing the LLSRS between
the two groups. Target end-tidal CO2 ( PETCO2) will be measured to objectify adequate
hyperventilation. Symptoms of hypocapnia due to the (pre-)intervention as well as any
adverse events will be reported and analysed.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02760121 -
AZ, MZ, and the Pulmonary System Response to Hypoxia
|
Phase 4 | |
Completed |
NCT01465971 -
Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude
|
N/A | |
Recruiting |
NCT04915365 -
Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude
|
Phase 3 | |
Withdrawn |
NCT02941510 -
Inhaled Budesonide for Altitude Illness Prevention
|
Phase 3 | |
Completed |
NCT04075565 -
The Psychophysiological Effect of Simulated and Terrestrial Altitude
|
N/A | |
Active, not recruiting |
NCT04913389 -
Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD
|
Phase 3 | |
Completed |
NCT01171794 -
Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)
|
Phase 3 | |
Completed |
NCT04751292 -
HIGH Altitude CArdiovascular REsearch Latin America Population Study
|
||
Completed |
NCT02024386 -
Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
|
Phase 4 | |
Recruiting |
NCT02780908 -
Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely
|
N/A |